ReviewDigestive diseases and sciences2021
Mast Cell Activation Syndrome: A Primer for the Gastroenterologist.
Review in Digestive diseases and sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- A Clinical Practice Update for the Management of Patients With Disorders of Gut-Brain Interaction and Altered Food Intake Behavior.Neurogastroenterology and motility · 2026Guideline
- Pathophysiological Drivers of Mast Cell Activation Syndrome and Implications for Treatment.Fortune journal of health sciences · 2026Article
- Gastrointestinal Manifestations and Nutrition Support in Hypermobile Ehlers-Danlos, Postural Orthostatic Tachycardia, and Mast Cell Activation Syndromes.Current gastroenterology reports · 2026Review
- Irritable bowel syndrome with diarrhea: time to change practice?Current opinion in gastroenterology · 2026Review
- Role of Mast Cells and Neuroinflammation in Neuropsychiatric Disorders of the Developmental Period.Biomolecules · 2026Review
- Eosinophilic and mastocytic gastrointestinal diseases: current knowledge and controversy in histopathologic diagnosis.Translational gastroenterology and hepatology · 2026Review
- Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome.Brain, behavior, & immunity - health · 2025Article
- Hewei Jiangni granule alleviates visceral hypersensitivity of non-erosive reflux diseasestromal interaction molecule 1/transient receptor potential vanilloid subfamily member 1 pathway.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Spectrum, Time Course, Stages, and a Proposal for the Diagnosis of Histamine Intolerance in General Practice: A Nonrandomized, Quasi-Experimental Study.Journal of clinical medicine · 2025Article
- Cardiovascular manifestations in mast cell activation disease: key insights for cardiologists and angiologists.Frontiers in cardiovascular medicine · 2025Review
- Association of postural orthostatic tachycardia syndrome, hypermobility spectrum disorders, and mast cell activation syndrome in young patients; prevalence, overlap and response to therapy depends on the definition.Frontiers in neurology · 2025Article
- The Suggested Relationships Between Common GI Symptoms and Joint Hypermobility, POTS, and MCAS.Gastroenterology & hepatology · 2024Article
- Mast cell activation syndrome: An up-to-date review of literature.World journal of clinical pediatrics · 2024Review
- Imatinib and Trigger Avoidance for Mast Cell Activation Syndrome Presenting With Attacks of Abdominal Pain, Nausea, Vomiting, and Diarrhea.ACG case reports journal · 2024Article
- [Diagnosis and treatment of Dunbar syndrome].Schmerz (Berlin, Germany) · 2024Review
- Getting the BS out of Irritable Bowel Syndrome with Diarrhea (IBS-D): Let's Make a Diagnosis.Current gastroenterology reports · 2024Review
- Biopsy samples from patients with irritable bowel syndrome, but not from those with mastocytosis or unspecific gastrointestinal complaints reveal unique nerve activation in all gut regions independent of mast cell density, histamine content or specific gastrointestinal symptoms.Frontiers in neuroscience · 2024Article
- Chemical Intolerance and Mast Cell Activation: A Suspicious Synchronicity.Journal of xenobiotics · 2023Article
- A survey of the currently known mast cell mediators with potential relevance for therapy of mast cell-induced symptoms.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Irritable Bowel Syndrome-Like Symptoms in Quiescent Inflammatory Bowel Disease: A Practical Approach to Diagnosis and Treatment of Organic Causes.Digestive diseases and sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
Abstract
Mast cell activation syndrome is thought to be a common, yet under-recognized, chronic multi-system disorder caused by inappropriate mast cell activation. Gastrointestinal symptoms are frequently reported by these patients and are often mistaken by physicians as functional gastrointestinal disorders. This syndrome can be diagnosed by the medical history and measurable biomarkers. Gastroenterologists manage diseases associated with active inflammatory cells including neutrophils, lymphocytes, macrophages, and eosinophils. The mast cell has only recently been recognized as a major player in our specialty. Gastrointestinal disorders from mast cell mediators often present with apparent irritable bowel syndrome, dyspepsia, chronic or cyclical nausea, and heartburn. Individuals with mast cell activation syndrome experience significant delays in diagnosis. The gastrointestinal symptoms are often refractory to symptom-targeted prescription medications. Beyond avoiding triggers, the best therapy is directed at modulating mast cell activation and the effects of the mediators. Many of these therapies are simple over-the-counter medications. In this article, we review mast cell function and dysfunction and the gastrointestinal symptoms, comorbid conditions, diagnosis, and management of mast cell activation syndrome. Gastroenterologists who become aware of this syndrome can dramatically improve the quality of life for their patients who previously have been labeled with a functional gastrointestinal disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.